Analyst Price Target is $1.50
▲ +455.56% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for VYNE Therapeutics in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 455.56% upside from the last price of $0.27.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in VYNE Therapeutics. This Buy consensus rating has held steady for over two years.